Haemonetics Management
Management criteria checks 3/4
Haemonetics' CEO is Chris Simon, appointed in May 2016, has a tenure of 8.58 years. total yearly compensation is $11.55M, comprised of 9.4% salary and 90.6% bonuses, including company stock and options. directly owns 0.55% of the company’s shares, worth $20.85M. The average tenure of the management team and the board of directors is 3.4 years and 7 years respectively.
Key information
Chris Simon
Chief executive officer
US$11.5m
Total compensation
| CEO salary percentage | 9.4% |
| CEO tenure | 8.6yrs |
| CEO ownership | 0.6% |
| Management average tenure | 3.4yrs |
| Board average tenure | 7yrs |
Recent management updates
Recent updates
Investors Interested In Haemonetics Corporation's (NYSE:HAE) Earnings
Dec 06
These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well
Sep 09What You Can Learn From Haemonetics Corporation's (NYSE:HAE) P/E
Aug 14Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 46%?
Jul 18Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth
Jun 21Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?
Apr 30Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion
Apr 12Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate
Mar 07Haemonetics Corporation: Improved Performance, Another Bolt-On Deal
Mar 06The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business
Feb 15The Price Is Right For Haemonetics Corporation (NYSE:HAE)
Jan 01Haemonetics: Solid Performance Of This Blood Play
Nov 22Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today
Nov 14Is Haemonetics (NYSE:HAE) A Risky Investment?
Oct 24Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment
Oct 13Haemonetics' Fiscal Q1 2024: Blood, Sweat, And Stellar Gains
Aug 09Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors
Aug 09An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued
Jul 25Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet
Jul 07Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet
Apr 06Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?
Mar 19Haemonetics Executing Well, But Valuation Dogged By Concerns About A Large Customer
Feb 16Haemonetics: Earnings Rate Of Change Justifies High Multiples
Feb 01We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease
Jan 05Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?
Dec 15Haemonetics Q2 2023 Earnings Preview
Nov 04Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly
Oct 04Haemonetics: Plasma Thesis Continues To Play Out, Reiterate Buy
Sep 06Haemonetics reaches new 52-week high; shares up 41% YTD
Aug 24Haemonetics reports Q2 earnings beat; raises FY22 guidance
Aug 10A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)
Aug 10Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly
Jul 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 28 2024 | n/a | n/a | US$124m |
| Jun 29 2024 | n/a | n/a | US$115m |
| Mar 30 2024 | US$12m | US$1m | US$118m |
| Dec 30 2023 | n/a | n/a | US$127m |
| Sep 30 2023 | n/a | n/a | US$128m |
| Jul 01 2023 | n/a | n/a | US$137m |
| Apr 01 2023 | US$11m | US$1m | US$115m |
| Dec 31 2022 | n/a | n/a | US$96m |
| Oct 01 2022 | n/a | n/a | US$86m |
| Jul 02 2022 | n/a | n/a | US$68m |
| Apr 02 2022 | US$9m | US$945k | US$43m |
| Jan 01 2022 | n/a | n/a | US$23m |
| Oct 02 2021 | n/a | n/a | US$31m |
| Jul 03 2021 | n/a | n/a | US$64m |
| Apr 03 2021 | US$9m | US$963k | US$79m |
| Dec 26 2020 | n/a | n/a | US$108m |
| Sep 26 2020 | n/a | n/a | US$106m |
| Jun 27 2020 | n/a | n/a | US$96m |
| Mar 28 2020 | US$9m | US$937k | US$77m |
| Dec 28 2019 | n/a | n/a | US$80m |
| Sep 28 2019 | n/a | n/a | US$68m |
| Jun 29 2019 | n/a | n/a | US$49m |
| Mar 30 2019 | US$9m | US$894k | US$55m |
| Dec 29 2018 | n/a | n/a | US$46m |
| Sep 29 2018 | n/a | n/a | US$21m |
| Jun 30 2018 | n/a | n/a | US$23m |
| Mar 31 2018 | US$8m | US$858k | US$46m |
Compensation vs Market: Chris's total compensation ($USD11.55M) is above average for companies of similar size in the US market ($USD6.67M).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
CEO
Chris Simon (60 yo)
8.6yrs
Tenure
US$11,545,113
Compensation
Mr. Christopher A. Simon, also known as Chris, has been the Chief Executive Officer and President of Haemonetics Corporation since May 16, 2016 and has been its Director since May 2016. He joined Haemoneti...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 8.6yrs | US$11.55m | 0.55% $ 20.9m | |
| CFO, Executive VP & Financial Officer | 2.7yrs | US$3.15m | 0.0095% $ 359.6k | |
| Executive VP | 7.8yrs | US$3.07m | 0.039% $ 1.5m | |
| Executive Vice President of Global Manufacturing & Supply Chain | 6.3yrs | US$2.43m | 0.039% $ 1.5m | |
| VP, Chief Accounting Officer & Principal Accounting Officer | 2.2yrs | no data | 0.00027% $ 10.2k | |
| Senior Director of Investor Relations | 5.2yrs | no data | no data | |
| Senior Vice President of Strategy & Corporate Development | 1.7yrs | no data | no data | |
| Senior VP & Chief Human Resources Officer | 3.3yrs | no data | 0.023% $ 886.2k | |
| Senior VP & Chief Medical Officer | 1.7yrs | no data | no data | |
| President of Global Hospital | 5.3yrs | US$2.48m | 0.036% $ 1.4m | |
| Senior Vice President of Global Quality Assurance | 3.4yrs | no data | no data | |
| President of Global Plasma & Blood Center | 2.2yrs | no data | 0.0036% $ 136.8k |
3.4yrs
Average Tenure
53.5yo
Average Age
Experienced Management: HAE's management team is considered experienced (3.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 8.3yrs | US$11.55m | 0.55% $ 20.9m | |
| Independent Director | 7.2yrs | US$295.73k | 0.036% $ 1.3m | |
| Independent Director | 4.7yrs | US$283.73k | 0.016% $ 623.7k | |
| Independent Chairman | 6.9yrs | US$449.98k | 0.024% $ 923.7k | |
| Independent Director | 5.7yrs | US$269.95k | 0.019% $ 735.4k | |
| Independent Director | 18.9yrs | US$280.73k | 0.032% $ 1.2m | |
| Independent Director | 10.4yrs | US$292.95k | 0.036% $ 1.4m | |
| Independent Director | 3.3yrs | US$272.95k | 0.012% $ 438.0k | |
| Member of Scientific Advisory Council | no data | no data | no data | |
| Member of Scientific Advisory Council | no data | no data | no data | |
| Member of Scientific Advisory Council | no data | no data | no data | |
| Member of Scientific Advisory Council | no data | no data | no data |
7.0yrs
Average Tenure
70yo
Average Age
Experienced Board: HAE's board of directors are considered experienced (7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 03:33 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/28 |
| Annual Earnings | 2024/03/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Haemonetics Corporation is covered by 29 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daniel Owczarski | Avondale Partners |
| Ishan Majumdar | Baptista Research |
| Gary Prestopino | Barrington Research Associates, Inc. |